莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的疗效观察  

Study the Efficacy of Mosapride Combined with Rebamipide on the Treatment of Chronic Atrophic Gastritis

作　　者：陆军平 

机构地区：[1]佛山市南海区第四人民医院消化内科,广东佛山528211

出　　处：《现代诊断与治疗》2015年第2期250-252,共3页Modern Diagnosis and Treatment

摘　　要：目的：研究观察莫沙比利联合瑞巴派特与单用莫沙比利治疗慢性萎缩性胃炎的治疗效果比较。方法对我院2011年6月-2013年12月期间收治的慢性萎缩性胃炎病例进行研究，包括门诊和住院经病理确诊的245例。将这些病例按随机数表的方法随机分为两组，观察组给予莫沙比利联合瑞巴派特进行治疗，对照组给予莫沙比利治疗。对比观察观察组和对照组患者的治疗有效率和幽门螺杆菌的根除率。结果观察组使用莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的临床有效率和幽门螺杆菌的根除率明显高于对照组，其差异均有统计学意义（P〈0.05）。结论莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎相比于单纯使用莫沙比利具有更加明显的临床效果，可有效减少幽门螺杆菌的感染率而降低复发风险。Objec tive Discuss the clinical therapeutic of Mosapride combined with Rebamipide on the treatment of chronic atrophic gastritis Methods Choose our hospital treatments of 245 cases of patients with chronic atrophic gastritis, randomly divided into observation group and control group, observation group adopts the Mosapride combined with Rebamipide therapy treatment, con-trol group with Mosapride treatment, observe the clinical therapeutic effect of two groups and the status of helicobacter pylori eradication.Results The clinical therapeutic effect and Helicobacter py-lori eradication efficiency ratio of observation group was significantly higher than the control group, the differences were statistically significant （P〈0.05）. Conclusions Mosapride combined with Re-bamipide treatment of chronic atrophic gastritis are more obvious clinical effects compared with simply using Mosapride, which can effectively reduce the prevalence of H. pylori and reduces the risk of recurrence.

关 键 词：莫沙比利 瑞巴派特 慢性萎缩性胃炎 

分 类 号：R573.3[医药卫生—消化系统]